An Overview of the N=1 Collaborative and ASO Treatment for KCNT1
January, 23 - Winston Yan, President of N1C - “An Overview of the N=1 Collaborative” and Tim Yu, Geneticist & Neurologist, Boston...
An Overview of the N=1 Collaborative and ASO Treatment for KCNT1
Individualized ASO therapy for rare diseases
Hanging Our Hat on Shared Learnings
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N=1 Exon Skipping ASOs
NEW N1C Seminar Series
Democratizing drug development will be a win for all
Happy Holidays & A Call for Speakers and Participants in 2023
They Created a Drug for Susannah. What About Millions of Other Patients?